The authors report the results of a survey of UK cardiac anesthesiologists and surgeons on the effect of the withdrawal of aprotinin from clinical practice. The majority of respondents felt that suspension of aprotinin’s license had had no effect while a third felt it had impacted negatively on patient care. Given the biases involved, this survey presents little useful information for clinicians.

– Jean-Franois Hardy